

## Information for Authors

Revised February 2019

*eNeuro*, an open-access journal from the Society for Neuroscience, publishes high-quality, broad-based, peer-reviewed research focused solely on the field of neuroscience. *eNeuro* embodies an emerging scientific vision that offers a new experience for authors and readers, all in support of SfN's mission to advance understanding of the brain and nervous system.

**eNeuro is indexed** by Scopus, EMBASE, PubMed, PubMed Central, and Web of Science/ESCI.

- [General Information](#)
- [Policies](#)
- [Fees](#)
- [Preparing a Manuscript](#)
- [Submitting a Manuscript](#)
- [Revising/Finalizing a Manuscript](#)
- [Correcting Errors in Published Articles](#)

## General Information

### Types of Articles

#### Research Articles

*eNeuro* publishes research papers that contribute to field of neuroscience by expanding knowledge in areas of fundamental importance: Development, Neuronal Excitability, Sensory and Motor Systems, Integrative Systems, Cognition and Behavior, Novel Tools and Methods, Disorders of the Nervous System, and History, Teaching, and Public Awareness. *eNeuro* accepts standard and new research manuscripts in the following areas:

- **New Research:**
  - **Expanding knowledge:** Research articles that contribute to neuroscience literature by expanding knowledge in areas of fundamental importance.
  - **Failure to Replicate:** Research from authors who could not reproduce someone else's work of significant importance despite using the same methodology and experimental conditions (explaining why the reproduction failed is not mandatory). There are many reasons why something cannot be exactly replicated because we can't control all parameters such as a genetic shift, modified antibody, for

example. The Methods section needs to include the details and not just reference another paper.

- **Methods/New Tools:** Research papers that are well documented discussing new methods and tools useful to the scientific community.
- **Theory/New Concepts:** Research papers that are not necessarily based on experimental data and that question existing dogma.
- **Negative Results:** Research papers from authors who tried to test important hypotheses but did not get the outcome they expected. Failed preclinical tests are particularly welcome. These manuscripts must include testing the hypothesis by multiple experimental approaches, rigorously reproducing the experimental models of others that you claim to refute, and meticulous use of both positive and negative controls.
- **Confirmation:** Research papers from authors confirming they replicated someone else's work of significant importance and extended it.

### Registered Reports

Registered Reports are a form of empirical article in which the methods and proposed analyses are pre-registered and reviewed prior to research being conducted. High quality protocols are then provisionally accepted for publication before data collection commences. This format is designed to minimize bias in deductive science, while also allowing the flexibility to conduct exploratory (unregistered) analyses and report serendipitous findings.

See [Registered Reports: Guidelines for Authors](#) for more information.

### Feature Articles

- **Research Highlights:** Articles written by the Features Editor about recently published research in *eNeuro*. Aimed at a broad scientific audience, the research highlight places the new findings within the context of current scientific knowledge in the particular area of neuroscience to which the research relates. The research highlight also discusses future, real-world implications of the findings. The selection for the highlight is guided by reviewers' and editors' comments about its likely impact on the neuroscience community. The senior author of the research highlighted will have the opportunity to review the feature article prior to its publication.

### Reviews

Reviews provide timely, comprehensive, and conceptual advances and integration of a field or topic. They are

peer-reviewed articles and follow the same guidelines as research papers. There is no size limit.

## Societal Impact

Societal impact papers discuss and analyze the social and ethical aspects of research. Authors should make a pre-submission inquiry to the editor-in-chief if they wish to provide an article in this section.

## History of Neuroscience

History of neuroscience papers present how major discoveries were made, how a field evolved over time, the history of great neuroscientists, etc. Authors should make a pre-submission inquiry to the editor-in-chief if they wish to provide an article in this section.

## Commentaries

Commentaries are short articles (1-2 pages) that discuss any published article or issues of special interest. They must contain a critique of the importance of the research that is undertaken or provide an alternative view or improve on an idea or a theory. Authors should make a pre-submission inquiry to the editor-in-chief if they wish to provide an article in this section.

## Opinions

Opinions are short articles (2-4 pages) that present new ideas or discuss the state of a given research field.

## Post-Publication Commentary (or Letters to the Editor)

Responses to articles may be submitted online via the “Respond to this article” link on the article’s Web page.

Article responses allow readers to comment on the content of articles published in *eNeuro*. The goal is to facilitate open exchanges on science published in *eNeuro*. See [Letters to the Editor](#) for more information.

## Invited Articles

*eNeuro* publishes a variety of invited articles including review articles, opinions, and commentaries at the invitation of the editorial board. Invited articles are peer reviewed and follow the same guidelines as research articles.

## Policies

In submitting a manuscript to *eNeuro*, all authors must agree to abide by all relevant policies, including its [Guidelines for Responsible Conduct Regarding Scientific Communication](#). Manuscripts with multiple authors are reviewed with the explicit understanding that all authors

have seen and approve of the submitted version and agree to abide by the Society’s policies.

*eNeuro* recognizes its responsibility to ensure that questions of scientific misconduct or dishonesty in research are adequately pursued. Should scientific misconduct or dishonesty be suspected or alleged, *eNeuro* follows the recommended procedures outlined by [COPE](#) when dealing with allegations of misconduct.

## Policy on Ethics

Authors submitting papers to *eNeuro* must have conducted their work in strict accordance with the Society’s [Policy on Ethics](#). SfN follows the recommended procedures outlined by [COPE](#) when dealing with allegations of misconduct. In cases of authorship dispute after acceptance, *eNeuro* does not get involved and instead directs authors to follow the COPE guidelines outlined [here](#). Modifications to authorship will only be made if all authors provide written agreement.

## Policies on the Use of Animals and Humans in Neuroscience Research

All animal experimentation reported in *eNeuro* must have been conducted in accordance with the Society’s [Policies on the Use of Animals and Humans in Neuroscience Research](#).

## Policy on Prepublication

*eNeuro* generally does not consider manuscripts that have been previously published. Posting to a preprint server such as [bioRxiv](#), [ArXiv](#), [Open Science Framework](#), etc. are not considered prior publication. Authors who have posted to [bioRxiv](#) and [Authorea](#) have the option to transfer their files directly for consideration by *eNeuro*. Posting a manuscript to a preprint server while under consideration for *eNeuro* is allowed up until the point of acceptance. Abstracts, theses, posters, or manuscripts that have been posted on the Internet for the purpose of receiving commentary from the community are not considered prior publication. Online posting is typically done at a prepublication repository that has been designed for the purpose, but posting on an institutional website or other Internet location is acceptable. Articles submitted from a preprint server should comply with submission guidelines for a double-blind process as described at <http://eneuro.org/content/preparing-manuscript#organization>. Please contact [eNeuro@sfn.org](mailto:eNeuro@sfn.org) before submitting if you are uncertain that your manuscript meets the criteria for a double-blind review.

It is essential that the authors retain the copyright for any pre-published material that they submit to *eNeuro*, and that they are willing and able to relinquish to *eNeuro* any copyrights and/or licenses that *eNeuro* requires for publication of accepted manuscripts. Authors should realize that other journals might not consider pre-published material and that prepublication will restrict their

alternatives when a manuscript is not accepted by *eNeuro*.

## Policy on Molecular Data

*eNeuro* subscribes to the policies of *The Journal of Biological Chemistry* on protein and nucleic acid sequences and genomic and proteomic data, which it modifies as follows:

**Protein and nucleic acid sequences:** Newly determined nucleotide or protein sequences must be deposited in [GenBank](#), [EMBL](#), or the [DNA Databank of Japan](#). Accession numbers must be reported in the manuscript and data must be available upon acceptance and publication of the manuscript. No data are to be withdrawn following publication.

**Genomic and proteomic data:** Authors of papers that include functional genomics data such as microarray, ChIP seq, RNA-seq, or other high-throughput data are required to deposit the data in a MIAME-compliant database such as [GEO](#), [ArrayExpress](#), or [CYBEX](#) and to provide accession numbers. Data must be publicly accessible upon acceptance and publication of the manuscript. No data are to be withdrawn following publication.

Authors of papers that include proteomics data should comply with the [guidelines developed by Molecular and Cellular Proteomics](#).

## Policy on Computer Code and Software

**Computational models:** New computational neuroscience computer code must be included with the initial submission as [Extended Data](#) to ensure reproducibility if published and be deposited in a suitable repository such as [GitHub](#), [ModelDB](#), [BioModels](#), [CellML](#), or [Visiome](#). Studies using custom code deemed central to the conclusions must include a statement in the Materials and Methods section, under the heading "Code Accessibility", indicating whether and how the code can be accessed, including any accession numbers or restrictions, and be cited in the references. The type of computer and the operating system used to run the code in the manuscript must be included in the Materials and Methods section. Code must be available upon acceptance and publication of the manuscript. No code is to be withdrawn following publication. Code files must be packaged in a single ZIP file.

**Software:** If new software or a new algorithm is used for data analysis, authors are encouraged to include the software or algorithm with the submission as [Extended Data](#) and deposit it in an appropriate public repository. A statement needs to be included in the Materials and Methods section, under the heading "Software Accessibility", indicating whether and how the software or algorithm can be accessed, including any accession numbers or restrictions. Software files must be packaged in a single ZIP file.

## Policy on Image Manipulation

*eNeuro* subscribes to the policy of *The Journal of Cell Biology* on image manipulation, which it modifies as follows.

**Original data:** Editors reserve the right to request any original data from authors at any stage in the submission, review, or publication process, including after publication. Failure to provide requested information may result in publication delays or revocation of acceptance.

**Image manipulation:** All images in manuscripts accepted for publication will be scrutinized by our production department for any indication of manipulation that is inconsistent with the following guidelines. Manipulation that violates these guidelines may result in production delays or revocation of acceptance.

- No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
- Constructing figures using images taken from different parts of the same gel, or from different gels, is discouraged. But when this is necessary it must be made explicit by the arrangement of the figure (e.g., using dividing lines) and in the text of the figure legend.
- Recordings obtained at different time points or from different sites must not be spliced together to give the appearance of a continuous record. Authors must make it clear in the figure legend how many different recordings are illustrated.
- Adjustments to images or recordings are acceptable if they are applied uniformly to all portions of the image or recording, and as long as they do not obscure, eliminate, or misrepresent information present in the original, including the background. Adjustments involving filtering or scaling (e.g., brightness, contrast, or color balance) must be applied to every pixel in the image or applied uniformly to an entire recording. Non-linear adjustments (e.g., changes to gamma settings) or deleting portions of a recording (e.g., leak subtraction or stimulus artifacts) must be disclosed in the figure legend.
- The minimum resolution for images is 300 dpi.
- At the time of acceptance, authors will be required to submit uncropped images of complete gels for comparison to the prepared figures. If original data cannot be produced, the acceptance of the manuscript may be revoked.

**Scale bars:** All illustrations documenting results must include a bar to indicate the scale.

**Molecular weights and fragment sizes:** The migration of protein molecular weight size markers or nucleic acid size markers must be indicated and labeled appropriately (e.g., "kD," "nt," "bp") on all figure panels showing gel electrophoresis.

## Policy on Copyright

Copyright of all material published in *eNeuro* remains with the authors. The authors grant the Society for Neuroscience a license to publish their work. Immediately upon publication, the work becomes available for the public to copy, distribute, or display under the [Creative Commons Attribution 4.0 International \(CC BY 4.0\) license](#). Per the terms of the license, it is not necessary to obtain permission or pay a fee to reuse this material, provided the authors receive proper acknowledgment.

The corresponding author may sign the license agreement on behalf of all authors, except authors who are NIH employees. Each author employed by NIH must complete and sign an [NIH Publishing Agreement](#) and attach it to an unsigned *eNeuro* [License to Publish form](#).

## Policy Concerning Availability of Materials and Data

By publishing a paper in *eNeuro* the author(s) agree to make freely available to colleagues in academic research any clones of cells, nucleic acids, antibodies, etc. that were used in the research reported and that are not available from commercial suppliers.

Authors should, when possible, honor requests for access to any form of published data for appropriate scientific use. The editors reserve the right to request any original data from authors at any stage in the review or publication process, including after publication. Failure to provide requested information may result in publication delays or revocation of acceptance.

## Embargo Policy

All articles appearing in *eNeuro* are embargoed for release to the public until 5 p.m. Eastern Standard Time on the evening before the publication date. This policy applies to members of the media, authors, local institutions' public information officers, and anyone else with access to articles published in *eNeuro*. If you would like to know when an article will be posted online, please send an email inquiry to [eNeuro@sfn.org](mailto:eNeuro@sfn.org). If a reporter contacts an author independent of any media relations effort, an author may share the manuscript and speak about it with the reporter as long as both parties understand that the release date is after the embargo is lifted.

## NIH Public Access Policy

NIH and certain private funding agencies require that a final electronic version of manuscripts describing research that they supported be submitted to the National Library of Medicine's PubMed Central site. Information

about the NIH policy can be found at <http://publicaccess.nih.gov>.

As a service to our authors, *eNeuro* will deposit final versions of manuscripts in PubMed Central if the research was funded by NIH, Howard Hughes Medical Institute, or the Wellcome Trust. Authors funded by these agencies should accurately describe the source of funding in the acknowledgments section of their manuscripts.

Although NIH policy calls for manuscripts in PubMed Central to be freely accessible after 12 months, *eNeuro* will allow manuscripts to be publicly accessible through PubMed Central immediately upon publication, which is when all *eNeuro* articles become freely accessible.

This service will be provided automatically, without a fee, and should fulfill the obligations that grantees of these agencies have in complying with the NIH Public Access Policy for articles published in *eNeuro*.

## Fees

### No Submission Fee

### Article Processing Fees

To offset expenses associated with *eNeuro*'s editorial process — including peer-review management, data tagging and composition, copyediting, online hosting and archiving, and publishing — the journal charges a publication fee to the authors, institutions, or funders for each article published. These fees will be billed to the corresponding author upon acceptance of the article. There is no fee for invited articles. Authors are not charged for color figures, tables, or multimedia.

Publication fees are discounted if the first and last authors are members of the Society for Neuroscience. **For a limited time, there is a discounted Publication fee as noted below.**

- Research articles, History of Neuroscience, Societal Impact, Registered Reports, and Review articles: \$1,950 for members and \$2,925 for nonmembers.
- Commentaries and opinions: \$975 for members and \$1,465 for nonmembers.
- Wire transfer fee: \$25.00.

If you would like to join SfN and take advantage of membership, visit our [Member Center](#). Accepted manuscripts will not be published until payment has been received.

### Funder Compliance

Authors retain copyright of their work and grant SfN license to publish under a [Creative Commons Attribution 4.0 International](#) (CC BY 4.0) license.

This Creative Commons license complies with funders who require an unrestricted attribution license at time of acceptance, including [Wellcome Trust](#), [Charity Open Access Fund\\*](#) (COAF), and [UK Research and Innovation\\*\\*](#) (RCUK).

For authors whose work is funded by NIH, Howard Hughes Medical Institute, Wellcome Trust, or UKRI, *eNeuro* will deposit the final published article to PubMed Central (PMC) and/or Europe PMC.

*\*COAF includes a partnership between six UK medical research charities: Arthritis Research UK, Breast Cancer Campaign, the British Heart Foundation, Cancer Research UK, Leukaemia & Lymphoma.*

*\*\*UKRI includes nine different research bodies: MRC, BBSRC, AHRC, ESRC, EPSRC, NERC, STFC, Innovate UK, and Research England.*

## Reduced Charges

Fees will be reduced if the first and last authors are members of the Society for Neuroscience and have work addresses in one of the countries in the categories listed below. If the first and last authors work in countries in different categories, the country with the less reduced fee applies.

In an effort to aid neuroscientists working in resource-restricted countries and to broaden the dissemination of science to all areas of the world, *eNeuro* offers reduced submission and publication fees to scientists located in the countries classified by the World Bank as low-income economies ([Category I](#)), lower-middle-income economies ([Category II](#)), or upper-middle-income economies ([Category III](#)).

All publication fees will be reduced to 25 percent of the usual amount for Category I countries, and will be reduced to 50 percent of the usual amount for countries in Category II and III.

## Payment

Fees should be paid by credit card. If a credit card cannot be used, a check or wire transfer can be accepted. Purchase orders are no longer accepted.

## Help

For payment questions, please contact the *eNeuro* central office at [eNeuro@sfn.org](mailto:eNeuro@sfn.org).

## Contact Information

### Society for Neuroscience Central Office

*eNeuro*  
Society for Neuroscience  
1121 14th Street, NW, Suite 1010  
Washington, DC 20005 USA  
Email: [eNeuro@sfn.org](mailto:eNeuro@sfn.org)  
Phone: (202) 962-4000

### Editor-in-Chief

Dr. Christophe Bernard  
INSERM U1106  
Faculté de Médecine Timone  
27 Bd Jean MOULIN  
Institut de Neurosciences des Systemes  
13365 Marseille Cedex 05  
France  
Email: [eNeuroeditor@sfn.org](mailto:eNeuroeditor@sfn.org)

## Letter of Recommendation

As a service to our authors, *eNeuro* will provide a Letter of Recommendation to assist with their career progression on behalf of any author who has published a paper in *eNeuro*, if requested. The Letter of Recommendation will be signed by the Reviewing Editor of the paper, the Advisory Board member, and the Editor in Chief who can say with confidence the articles in *eNeuro* are highly suitable for the most competitive journals. Email questions and requests to [eNeuro@sfn.org](mailto:eNeuro@sfn.org).

## Preparing a Manuscript

### Standard Manuscripts

#### Organization of the Manuscript

Manuscripts must be written in English. The entire text should be double-spaced, including references. Submitting an incomplete manuscript or a manuscript that does not adhere to the word limits will cause a delay in review. There are no overall length limitations.

Multiple-part papers are discouraged. Although this arrangement is sometimes necessary, authors will often be asked to collapse multiple papers into a single manuscript.

***eNeuro* uses a double-blind review process\***, which means the identities of both the authors and reviewers are concealed throughout the review process. In order to facilitate this, authors should ensure their manuscripts are prepared in a way that does not reveal their identity. Please use the following as a guide when submitting your paper:

- Eliminate author names and contact information from anyplace in the paper. See [Title Page](#) for more information.
- Use the third person to refer to personal work. For example, replace any phrases like 'as we have shown before' with 'has been shown before (Anonymous, 2007).'

- Make sure that the materials and methods section does not refer to personal work. Do not include statements such as ‘using the method described in (XXX, 2007).’ See [Materials and Methods](#) for more information.
- Ensure that figures do not contain any affiliation-related identifier.
- Depersonalize the work by using anonymous text where necessary. Do not include statements such as ‘as we have reported before.’
- Remove self-citations and citations to unpublished work.
- Do not eliminate essential self-references or other references, but limit self-references only to papers that are relevant for those reviewing the submitted paper.
- Remove references to funding sources.

It is the responsibility of the authors to comply with the rules outlined above to ensure anonymity. If you feel the necessary revisions cannot be made to meet the criteria for a double-blind review, please alert *eNeuro*’s central office ([eNeuro@sfn.org](mailto:eNeuro@sfn.org)) to inquire whether your manuscript may proceed with a non-double-blind review of the manuscript.

*eNeuro* uses a new policy regarding statistical analysis. Please refer to [Materials and Methods](#) and the statistical table section for more information. It is the responsibility of the authors to comply with these rules. If the type of statistical analysis is not mentioned or the statistical table not included, the manuscript will be pulled from review and sent back to the authors to make the necessary revisions.

New submissions may be submitted as one PDF containing all manuscript text, figures, and tables. Revised submissions must include the manuscript text and tables prepared in Word, WordPerfect, RTF, LaTeX, or Text format. Each figure should be submitted as an EPS or TIFF file and have a resolution of at least 300 DPI. A separate title page must be provided.

*\*Authors are welcome to submit a pre-submission inquiry to [eNeuro@sfn.org](mailto:eNeuro@sfn.org) if they feel their manuscript might not contain appropriate criteria for a double-blind review.*

## Supplemental Material, Extended Data, and Appendices

*eNeuro* does not accept supplemental material or appendices. Authors should make sure all necessary data including extended data and figures essential to the work are included with the submission. Theoretical papers should include enough detail about the models so that the work can be replicated.

## Extended Data

All Extended Data will be reviewed by the editors to determine whether it is integral to the study and should be included in the final version of the manuscript:

1. If there is a well-established repository for the data, it should be deposited there; *eNeuro* will host data without such a repository (see [Policy on Molecular Data](#) and [Policy on Computer Code and Software](#)).
2. Citations may not exist solely within the Extended Data; they must be included in the manuscript. Online data sets are still not visible to search engines used by citation indices, making inclusion of references in the main manuscript essential to provide proper credit to those cited.
3. Only Extended Data directly related to, or supporting figures or tables and corresponding figure legends are allowed. Extended Data should be provided in figure or table format and labeled as Figure 1-1, Figure 1-2, Table 1-1, Table 1-2, etc., so they indicate which figure or table they are supporting (i.e. Extended Data table supporting Figure 5 labeled as Figure 5-1). Each should have a legend and be cited in the manuscript text and in the table or figure legend for which they support. Extended Data that supports more than one figure and/or table should be labeled as supporting the figure or table referred to first in the text.
4. For ease of access and review, Extended Data should be submitted in the same format and following the same guidelines as regular figures and tables and uploaded to the system as Multimedia/Extended Data file type (see [Multimedia, Figure, and Table Guidelines](#)). Send an inquiry to [eNeuro@sfn.org](mailto:eNeuro@sfn.org) prior to submission if you wish to include Extended Data in other formats.
5. A limitation of 20 MB is recommended. Send an inquiry to [eNeuro@sfn.org](mailto:eNeuro@sfn.org) if larger files are needed.

## Code and Software

If a study includes computational work and/or modeling with code that the authors wrote for this study, and the computational work is deemed central to the conclusions of the study by the editors, the following is required for compliance with the [Policy on Computer Code and Software](#):

1. The code used for the submission should be uploaded to an online repository by the time the manuscript is accepted. To preserve the double-

blind review process, this URL should be redacted in the manuscript while under review and included in the cover letter.

2. The code files must be packaged into a single ZIP file, uploaded to the submission system as a "Multimedia/Extended Data" file type.
3. A legend for the code file, labeled as "Extended Data 1," should be at the end of the manuscript.
4. A subsection titled "Code Accessibility" should be included in the Materials and Methods section, stating: "The code/software described in the paper is freely available online at [URL redacted for double-blind review]. The code is available as Extended Data." The full statement, including the redacted URL, should be included in the cover letter to be used if the article is accepted. If there are any accession numbers or restrictions on accessing the code in the repository, these should be included in the full statement.
5. The type of computer and operating system on which the code was run to obtain the results in the manuscript must be stated in the Materials and Methods section.

Studies including any custom computational work, analysis, or modeling are encouraged to follow the guidelines above in the initial submission of the manuscript. If the editors deem your computational work central to the conclusions of your manuscript, and the code was not included as described above, you will be asked to provide your code in accordance with these instructions.

Studies for which analysis or modeling software was written must include a subsection in the Materials and Methods section titled "Software Accessibility." It is encouraged, but not required, for software to be uploaded to the submission and deposited in a repository in accordance with the instructions above. If the software is not published with the article, authors must provide their software to another scientist upon request.

## Title Page – Separate from Manuscript Text

The title page of the manuscript should be completed using the [Title Page Template](#).

Please include all the information listed and upload as a title page file.

Collect the following information to fill in the title page template:

- Title (50-word maximum)
- Abbreviated title (50-character maximum)
- [Author names and affiliation, including postal codes](#)
- Author contributions
- Corresponding author with complete address, including an email address and postal code
- Number of figures, tables, multimedia (separately)
- Number of words for abstract, introduction, and discussion (separately)
- [Acknowledgements](#)
- [Conflicts of Interest](#)
- Funding sources

## Submitting and Corresponding Authors

*eNeuro* distinguishes between submitting and corresponding authors. The submitting author is the author who submits the manuscript. A manuscript can have only one submitting author. The submitting author acts on behalf all other authors and is the only author with authority to resubmit, withdraw, correct, or retract manuscripts and published articles.

The corresponding author is the author responsible for responding to reader queries about the article. The submitting author has the option to also serve as corresponding author. *eNeuro* allows two authors to be designated as "corresponding authors." When two authors are listed, no priority is given. Corresponding authors do not have the authority to correct or retract a published article.

## Author Names

Authors who normally write their names in non-Latin characters may include their names in their native writing system in parentheses immediately following a transliterated version, for example, Jingbing Xue (薛晶冰). Any non-Latin languages that can be represented in Unicode characters will be accepted. This second rendering is allowed only for the original written form of a transliterated name and may not be used to include nicknames, degrees, ranks, titles, etc. Please size the name, including the surrounding parentheses, in your title page file so that it can be used as a graphic to produce the name in the final article.

The name of a formal group or consortium may be included in the author list only if that group made essential contributions to the results and there is at least one individual author in addition to the group. The individual authors must be listed first, followed by, "for [Group Name]." We do not allow "and [Group Name]." The group name must be spelled out. A statement in the

acknowledgements section may specify the contribution(s) of the group and may include a URL that provides more information about the group (such as a list of its membership), but it may not list individual group members or differentiate contributions made by subgroups or individuals within the group.

### *Author Affiliations*

The author's affiliation should be their home institution at the time when their primary contribution to the research was made. If an author's current affiliation differs, the current affiliation may be listed separately in the acknowledgements section.

### *Acknowledgements*

Acknowledgements should be used to identify all funding sources. Acknowledgements may also be used to note intellectual, technical, or other assistance that does not warrant authorship. Individuals should be informed before the publication of any such acknowledgements and given the opportunity to decline the recognition. Promotional statements are not permitted. Funding sources should be listed first, with any acknowledgements of assistance following.

### *Dedications*

*eNeuro* generally does not allow dedications. The only exception is dedications to recently deceased neuroscientists who made a specific scientific contribution to the work described in the article. If the recently deceased person was one of the authors of the current paper, his or her date of death should be included. *eNeuro* does not allow dedications to living people.

### *Conflict of Interest*

Conflict of interest declarations are included in the acknowledgments section. For "no conflict," the preferred wording is: "The authors declare no competing financial interests." It is expected that authors submitting papers to *eNeuro* are in accordance with the Society's [Policy on Conflict of Interest](#).

## Manuscript Text

Manuscripts must include the following sections in the order listed:

- [Abstract](#) (250 word maximum)
  - [Visual Abstract](#)
- [Significance Statement](#) (120 words maximum)
- [Introduction](#) (750 words maximum, including citations)
- [Materials & Methods](#)
- [Results](#)
- [Discussion](#) (3,000 words maximum, including citations)
- [References](#)
- [Legends](#)

- [Multimedia, Figure, and Table](#)

**Remember:** Do NOT include the title page or any information that could reveal any author's identity.

All lines of text should be numbered. Line numbers are automatically added in Microsoft Word documents.

### **Abstract (250 words maximum, including citations)**

The abstract should be clearly written and readily comprehensible to the broad readership of *eNeuro*. It should provide a concise summary of the objectives, methodology (including the species studied), key results, and major conclusions of the study. The abstract should be written in complete sentences, without subheadings. An abstract is not necessary for commentary, opinion, or review manuscripts.

Also available: [Visual Abstracts](#)

### **Significance Statement (120 words maximum)**

The significance statement should provide a clear explanation of the importance and relevance of the research in a manner accessible to researchers without specialist knowledge in the field and informed lay readers. The Significance Statement will appear within the paper below the abstract.

### **Introduction (750 words maximum, including citations)**

The introduction should briefly indicate the objectives of the study and provide enough background information to clarify why the study was undertaken and what hypotheses were tested.

### **Materials and Methods**

The materials and methods section should provide sufficient information to allow other investigators to repeat the research (see also [Policy Concerning Availability of Materials](#)). Previously published work by the authors must not be referenced but rather described in detail at least for the review process. Once the paper is accepted the authors may add the relevant references. Reference to publish procedures can be made if these procedures are commonly accepted by the scientific community. The sex of the species studied should be stated. All companies from which materials were obtained should be listed. If materials were obtained from an individual, an affiliation for that individual should be listed. A manuscript that presents only a theory may omit the materials and methods section.



All animal experimentation reported in *eNeuro* must have been conducted in accordance with the Society's [Policies on the Use of Animals and Humans in Neuroscience Research](#).

**To preserve the double-blind process** please use the following statement regarding animal use: "All animal procedures were performed in accordance with the [Author University] animal care committee's regulations." The full statement including the name of the institution should be included in the cover letter to be used if the article is accepted.

Regarding the location where human subjects were recruited please use the following statement: 'Human subjects were recruited at a location which will be identified if the article is published.' The full statement including the location should be included in the cover letter and will be used if the article is accepted.

### Statistics

Numerical data should be analyzed using appropriate statistical tests. The authors must state the statistical methods they have used: descriptive and/or experimental design. In the case of experimental design, the authors must indicate the type: nonrandom or random (non-inferiority or superiority).

### URLs

*eNeuro* encourages the use of links to Web pages providing detailed specification for animal lines, reagents, software packages, etc., when it is impossible or impractical to include a unique identifier or unambiguous description. URLs should be cited in parentheses in the text. For example: "Experiments were done using C57BL mice (<http://jaxmice.jax.org/strain/013636.html>)."

URLs of sites providing tutorial material (e.g., <http://en.wikipedia.org/>) are not allowed in articles because their authority and permanence cannot be verified.

URLs of personal or laboratory websites or Dropboxes are also prohibited to maintain author and reviewer anonymity.

### RRIDs

*eNeuro* is pleased to be part of the Resource Identification Initiative, a project aimed at clearly identifying the key resources used in the course of scientific research. This project helps address concerns about reproducibility by providing unique searchable identifiers, Research Resource Identifiers (RRIDs), for critical reagents and tools. RRIDs link readers to external resources and enable search engines to return all papers utilizing specified antibodies, organisms, or tools. This initiative is completely voluntary for *eNeuro* authors. RRIDs offer an important means for ensuring reproducible methods and providing critical data to help researchers identify suitable

reagents and tools. We encourage all *eNeuro* authors to participate.

### How to Find an RRID

In order to obtain an RRID visit <https://scicrunch.org/resources> and enter your search term(s).

- Search tip for antibodies: searching for the catalog number usually narrows the search to only a few relevant results.
- Search tip for organisms: you can include PubMed IDs (PMIDs) in your search or filter your search results by PMID, species, phenotype, and other criteria.
- Search tip for cell lines: searching for the catalog number of an established cell line is usually best, searching for common cell lines such as HeLa cells is expected to produce several pages of results.
- Search for software tools: usually the name of the tool (MATLAB or ImageJ) or the institution where it is housed will bring back relevant results.

For more search tips and help, contact [rrii-help@scicrunch.org](mailto:rrii-help@scicrunch.org).

### How to Include RRIDs in Your Paper

Once you have located an RRID, please insert "RRID:" plus the identifier in the appropriate location in the methods section. For example:

- Antibodies: "Sections were stained with a rabbit polyclonal antibody against ERK1 (Abgent Cat# AP7251E, RRID: AB\_2140114)."
- Cell Lines: "Subjects include the following cell line: CLS Cat# 300384/p699\_HeLa\_S3, RRID:CVCL\_0058."
- Genetically modified organisms: "Subjects in this study were Fgf9Eks/Fgf9+ mice (RRID: MGI\_3840442)..."
- Software tools: "...terminals were mapped with a computer-assisted mapping program (NeuroLucida, v 10; MicroBrightField RRID:nif-0000-10294)."

### How to Request an RRID

When you cannot find an RRID for a model organism or antibody that you used, you can help this initiative by submitting the reagent for an identifier as detailed below. The Resource Identification Portal includes mouse, zebrafish, worm, fruit fly, and rat model organisms as well as many commercial antibodies and some lab-sourced ones. When utilizing a model organism outside those already in the relevant model organism database, visit <https://scicrunch.org/resources/about/guidelines#organism> to submit a new organism." Antibodies can be added via the Antibody Registry

(<http://antibodyregistry.org/add>); please note that login is required on that site.

### Re-Analysis of Published Data

Reanalyses of published data are allowed if the original study reporting the data collection is clearly and thoroughly cited, if there are no duplications of figures or graphs that have already been published, and if the study clearly acknowledges that this is a previously acquired data.

### Statistical Table

The first column is the structure of the data (e.g., normal distribution).

The second column lists the statistical test.

The third column gives the observed power value of the statistical test calculated from the actual data. Confidence intervals may instead be listed.

The lines refer to the numerical values provided in the text as they appear in the results section.

	Data structure	Type of test	Power
a			
b			
c			

The following resources offer helpful guidelines on how to report statistical results:

- Bailar, JC, Mosteller, F (1988) Guidelines for statistical reporting in articles for medical journals. *Ann Intern Med*, 108:266-273
- Curran-Everitt, D, Benos DJ, (2004) Guidelines for reporting statistics in journals published by the American Physiological Society. *J Neurophysiol*, 92:669-671
- Lang, TA, Secic, M (2006) *How to report statistics in medicine: annotated guidelines for authors, editors and reviewers*, 2nd edition, Philadelphia, PA, ACP Press
- Sarter M, Fritschy JM (2008) *Eur J Neurosci* 28:2363-2364.

## Results

The results section should clearly and succinctly present the experimental findings. Only results essential to establish the main points of the work should be included. There is no limit in size or number of figures and tables for this section.

Authors must provide detailed information for each analysis performed, including population size, definition of the population (e.g., number of individual measurements, number of animals, number of slices, number of times

treatment was applied, etc.), and specific  $p$  values (not  $>$  or  $<$ ), followed by a superscript lowercase letter referring to the statistical table provided at the end of the results section. Numerical data must be depicted in the figures with box plots.

## Discussion (3,000 words maximum, including citations)

The discussion section should include a brief statement of the principal findings, a discussion of the validity of the observations, a discussion of the findings in light of other published work dealing with the same or closely related subjects, and a statement of the possible significance of the work. Extensive discussion of the literature is discouraged.

## References

Only published references should appear in the reference list at the end of the paper. The latest information on "in press" references should be provided. In the case of "in press" references (i.e., accepted for publication in a specific journal or book) the paper, which must be relevant for reviewers to see in order to make a well-informed evaluation should be included as a separate document text file along with the submitted manuscript. In this case, the authors recognize the loss of anonymity. "Submitted" references should be cited only in text and in the following form: (unpublished observations). If the paper is accepted, the authors can then add their names (A. B. Smith, C. D. Johnson, and E. Green, unpublished observations). The form for personal communications is similar: (F. G. Jackson, personal communication). Authors are responsible for all personal communications and must obtain written approval from persons cited before submitting the paper to *eNeuro*. Proof of such approval may be requested by *eNeuro*.

References should be cited in the text as follows: "The procedure used has been described elsewhere (Green, 1978)," or "Our observations are in agreement with those of Brown and Black (1979) and of White et al. (1980)," or, with multiple references in chronological order: "Earlier reports (Brown and Black, 1979, 1981; White et al., 1980; Smith, 1982, 1984)...."

List of references should be double-spaced and papers should be given in alphabetical order according to the surname of the first author. In two-author papers with the same first author, the order is alphabetical by the second author's name. In three-or-more-author papers with the same first author, the order is chronological. The name of the author(s) should be followed by the date in parentheses, the full title of the paper as it appeared in the original together with the source of the reference, the volume number, and the first and last pages. Do not number or bullet the references. If the author list for a paper in the references exceeds 20, the paper should be cited as Author A et al. The following illustrate the format to be used:

## Journal article

Hamill OP, Marty A, Neher E, Sakmann B, Sigworth F (1981) Improved patch-clamp techniques for high-resolution current recordings from cells and cell free membrane patches. *Pflugers Arch* 391:85-100.

Hodgkin AL, Huxley AF (1952a) The components of membrane conductance in the giant axon of *Loligo*. *J Physiol (Lond)* 116:473-496.

Hodgkin AL, Huxley AF (1952b) The dual effect of membrane potential on sodium conductance in the giant axon of *Loligo*. *J Physiol (Lond)* 116:497-506.

## Book

Hille B (1984) *Ionic channels of excitable membranes*. Sunderland, MA: Sinauer.

## Chapter in a book

Stent GS (1981) Strength and weakness of the genetic approach to the development of the nervous system. In: *Studies in developmental neurobiology: essays in honor of Viktor Hamburger* (Cowan WM, ed), pp288-321. New York: Oxford UP.

Abbreviations of journal titles should follow those listed in the *Index Medicus*. Responsibility for correct references lies with the author(s). After manuscript revisions, authors should double-check that all in-text citations are in the reference list and that all references on the reference list have at least one corresponding in-text citation. Failure to do so will result in the delay of proof generation and possibly publication. *Please make sure that the references are double-spaced and no bullets, numbers, or other listing formats are used.*

## Legends

Manuscripts that include figures, tables, multimedia, and/or extended data must include legends as part of the main manuscript text. Each file must have a separate legend and be numbered independently. The text of the article should refer to figures as "Figure 1," "Figure 2," etc., tables as "Table 1," "Table 2," etc., videos as "Movie 1," "Movie 2," etc., and Extended data as Figure 1-1, Figure 1-2, Table 1-1, Table 1-2, etc. These text citations of figures, tables, multimedia and extended data need to be in numerical order, in part to aid in placing the illustrations in the proper position on the PDF page. Note: Extended Data must be referenced in the table or figure legend for which they support.

## Multimedia, Figure, and Table Guidelines

eNeuro now permits extended data sets to be included with submissions (see [Extended Data](#))

## General Guidelines for Illustrations

*Image Manipulation:* Illustrations must conform to eNeuro's [Policy on Image Manipulation](#). Authors must retain their unprocessed data and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data are unavailable, manuscript evaluation may be halted until the issue is resolved. If the original data cannot be produced, the manuscript may be rejected.

*Use of Color:* Illustrations must be prepared so that they are accessible to our many color-blind readers. The following sites contain useful information, tips and tools on appropriate use of color in illustrations:

- <http://jfly.iam.u-tokyo.ac.jp/color/index.html>
- <http://webdesign.tutsplus.com/articles/design-theory/designing-for-and-as-a-color-blind-person/>
- <https://www.toptal.com/designers/colorfilter>

The following guidelines should be observed:

- Avoid gratuitous color: Grayscale generally provides a more faithful representation when a single quantity is being displayed. Use textures or different line types rather than colors in bar plots or graphs.
- Avoid troublesome color combinations: Figures with red and green are particularly problematic. Illustrations using green/red should generally be converted to green/magenta. If no suitable combination can be found, consider presenting separate monochrome images for the different color channels. For line drawing that require color, consider redundant coding by adding different textures or line types to the colors.

## Multimedia

eNeuro will publish multimedia embedded in the HTML and PDF versions of articles. Essential multimedia will be displayed in line with the article text, as is done for figures.

### Text Citation

Multimedia files must be numbered independently of figures and tables, and cited at the relevant point in the manuscript text (e.g., "Movie 1," "Movie 2").

### Title

A title should be part of the legend and not lettered onto the multimedia file itself.

### Legends

A legend must be included in the manuscript document after the reference list. Legends should include sufficient

detail to be intelligible without reference to the text. Legends must define all symbols and include essential information, such as scale bar dimensions. If videos are not in real time and the time is not displayed in the video, the period represented must be stated in the legend. Rather than stating "See text," legends should be more specific; for example, "See Results."

### Size

Videos must be submitted at the size they are to appear in *eNeuro*. They should be the smallest size that will convey the essential scientific information and sized appropriately: 1 column (maximum width 8.5 cm), 1.5 columns (maximum width 11.6 cm), or 2 columns (maximum width 17.6 cm).

### Format

Multimedia files must be in MP4 format, and should not be larger than one megabyte.

To optimize videos for PC, tablet and smartphone viewing, we recommend formatting your videos with the following specifications:

- Video codec: H.264
- Audio codec: AAC
- Audio bit rate: 128 kbps
- Video resolution: 480 vertical lines or better
- Size: Maximum width of 480 pixels

To convert videos from other formats to MP4 format, the following resource is available at:

[http://download.cnet.com/Free-MP4-Video-Converter/3000-2194\\_4-75628166.html](http://download.cnet.com/Free-MP4-Video-Converter/3000-2194_4-75628166.html).

For each video submitted, authors should provide a preview image, or poster frame that best captures the main point of the video.

## Figures

### Text Citation

Figures must be numbered independently of tables and tables multimedia models and cited at the relevant point in the manuscript text, e.g. "Figure 1", "Figure 2", etc. Do not duplicate data by presenting it both in the text and in a figure.

Label extended data supporting figures as Figure 1-1, Figure 1-2, etc., so they indicate which figure they are supporting with a legend. They should be cited in the manuscript text or in the figure legend for which they support. (see [Extended Data](#)).

### Title

A title should be part of the legend and not lettered onto the figure.

### Legends

A legend must be included in the manuscript document after the reference list. Legends should include sufficient detail to be intelligible without reference to the text. Legends must define all symbols and include essential information, such as scale bar dimensions. Rather than stating "See text," legends should be more specific; for example, "See Results."

At *eNeuro*, we value and want to better acknowledge the contributions of individual authors. Corresponding authors are encouraged include specific individuals' contributions to data acquisition, analysis, or other responsibility resulting in a figure at the end of each legend. Please use the heading "Figure Contributions" and state each contribution with the author's full name.

*Figure Contributions:* John Smith performed the experiments; Jane Jones analyzed the data.

### Size

Figures must be submitted at the size they are to appear in *eNeuro*. They should be the smallest size that will convey the essential scientific information and sized appropriately: 1 column (maximum width 8.5 cm), 1.5 columns (maximum width 11.6 cm), or 2 columns (maximum width 17.6 cm).

### Format

- **Initial Submission** - Figures may be included in a single PDF file that contains the manuscript and all tables and figures.
- **Revised Submission or Resubmission** - Figures must be submitted only as separate files in TIFF or EPS format. **Note:** EPS images cannot use the **Adobe CoolType Utility**. This is not compatible with the current image processing guidelines used by our online hosting provider.

Color figures should be in RGB format and supplied at a minimum of 300 dpi. For figures in vector-based format, all fonts should be converted to outlines and saved as EPS (Encapsulated PostScript) to ensure that they are reproduced correctly.

Monochrome (bitmap) images must be supplied at 1200 dpi.

Grayscale images must be supplied at a minimum of 300 dpi.

Remove top and right borderlines (that do not contain measuring metrics) from all graph/histogram figure panels (do not box the panels in).

Do not include any two-bar graphs/histograms. Instead state those values in the text. Two-bar graphs/histograms are generally discouraged because the result can be conveyed more precisely and compactly with numbers.

To ensure that your figures will appear at the highest quality, please review the detailed instructions for figure preparation with [Cadmus Digital Art](#). To better assist our authors with digital art preparation, *eNeuro* has made available Cadmus' Rapid Inspector application, which alerts users when their files do not meet acceptable specifications and provides instructions on how to reformat their files to meet those specifications. Sign up at the [Rapid Inspector website](#) to download the application. If you have problems downloading the application please see the FAQs at the Cadmus site.

## Tables

### *Text Citation*

All tables must be numbered independently of figures, multimedia and cited at the relevant point in the manuscript text, e.g. "Table 1," "Table 2," etc. Do not duplicate data by presenting it both in the text and in a table.

Label extended data supporting tables as Table 1-1, Table 1-2, etc., so they indicate which table they are supporting with a legend. They should be cited in the manuscript text or in the table legend for which they support. (see [Extended Data](#))

### *Title*

A title should appear above the table.

### *Legends*

A legend for each table must be included in the manuscript document after the reference list. Legends should include sufficient detail to be intelligible without reference to the text. Legends must define all symbols and include essential information, such as scale bar dimensions. Rather than stating "See text," legends should be more specific; for example, "See Results."

### *Format*

Each table should be double-spaced. Multiple-part tables (A and B sections with separate "subtitles") should be avoided when possible, especially when there are two [different] sets [or types] of column headings. Indentation of text and, sometimes, additional space between lines is preferred to highlight information. Avoid the use of color or shading, bold or italic fonts, or lines to highlight information.

Tables with color or shading in the table body will need to be processed as an illustration (graphic).

## Visual Abstract

Visual abstracts are a new way of summarizing journal articles into a single graphical image or schematic that is designed to emphasize the main findings of the article — the take-home message. Visual abstracts are intended to

help readers quickly identify papers that are most relevant to their areas of research.

**“A visual abstract should be eye-catching and easy to interpret.”**

Authors have the option of providing a visual abstract at submission or at revision. For ease of reading, visual abstracts should have a clear beginning and end — either from top to bottom or from left to right. Keep it simple. Content should be in graphical form; keep text to a minimum. Visual abstracts are considered a part of the technical content of the article and will go through the peer review process.

### *Size*

The visual abstract should be submitted at the smallest size that will convey the essential scientific information. It must be submitted at the final reduced size using the following guidelines to fit in 1 column (maximum width 8.5 cm), 1.5 columns (maximum width 11.6 cm), or 2 columns (maximum width 17.6 cm).

### *Format*

- **Initial Submission** — The visual abstract may be included in a single PDF file that contains the manuscript and all tables and figures.
- **Revised Submission or Resubmission** — The visual abstract must be submitted only as a separate file in TIFF or EPS format. Note: EPS images cannot use the Adobe\_CoolType\_Utility. This is not compatible with the current image processing guidelines used by our online hosting provider.

The visual abstract should be in RGB format and supplied at a minimum solution of 300 dpi. If in vector-based format, all fonts should be converted to outlines and saved in the EPS format to ensure that they are reproduced correctly.

To ensure that the visual abstract will appear at the highest quality, please review the detailed instructions for figure preparation with [Cadmus Digital Art](#). To better assist our authors with digital art preparation, *eNeuro* has made available [Cadmus' Rapid Inspector](#) application, which alerts users when their files do not meet acceptable specifications and provides instructions on how to reformat their files to meet those specifications. Sign up at the Rapid Inspector website to download the application. If you have problems downloading the application please see the FAQs at the Cadmus site.

## Mathematics and Equations

Manuscripts with many mathematical characters and equations should be prepared using MathType version

6.0 or higher (available from [Design Science, Inc.](#)). Our publisher can pull equations in this format directly from the text, thereby avoiding typographical errors that frequently occur in composing equations. Manuscripts with a minimal amount of math may be prepared using word-processing tools such as Word's Equation Editor, or with features such as bold, italics, superscript and subscript together with characters in the Symbol or Greek fonts. Do not use the Wingdings or Webdings fonts.

## Abbreviations

### List of Some Standard Abbreviations

Use nonstandard abbreviations only if a term appears three or more times (the initial appearance of the term and one other time). Spell out the term at first occurrence and introduce the abbreviation by placing it in parentheses after the term. Units should conform to the International System of Units (SI) (see the [International System of Units Brochure](#)), except for temperatures, which should be expressed in degrees Celsius.

### Preferred Usage

- The term “killed” is preferred to “euthanized” or “sacrificed,” which are considered euphemisms. If the word “killed” is objectionable, wording can be modified. For example, “the animal was exsanguinated” instead of “the animal was killed by exsanguination.”
- Italics are used for binomial nomenclature, gene names, genetically modified mice (e.g., mutants) and for certain Latin terms, but not for emphasis (e.g., “the Growth group,” not “the *Growth* group”).

## Letters to the Editor

Responses to articles may be submitted online via a link on the article's Web page.

Article responses allow readers to comment on the content of articles published in *eNeuro*. The goal is to facilitate open exchanges on science published in *eNeuro*. Responses can be submitted by first clicking the “Respond to this article” link on the right side of an article's Web page and then following the instructions provided. Please note that communications meant solely for the authors of an article, including requests for reprints, reagents, or assistance, should be sent instead to the address listed in the footnotes of the original article (after the phrase “Correspondence should be addressed to...”).

Responses should be concise: generally fewer than 250 words. It is acceptable to publish a more extensive commentary on an external site (e.g., ArXiv) and submit an abstract of that commentary with a URL as a response.

Responses will be screened for significance and appropriateness, and will usually be posted within 48 hours of receipt. Publication is at the discretion of the editors. *eNeuro* will not publish responses that, in our judgment, are not in the spirit of constructive scientific discourse and must provide evidenced-based facts. In addition, only one response (and optional reply to that response from the author) will be published for a given issue for a particular article. Although responses cannot be edited by the submitting author after publication, *eNeuro* editors reserve the rights to amend, edit, or remove materials at any time.

Certain material is inappropriate for responses. This includes, but is not limited to:

- Requests for medical advice or assistance
- Unpublished data (including figures or tables)
- Comments that advertise or promote specific commercial interests
- Comments that promote specific political or religious viewpoints
- Comments that are not supported by scientific facts
- Comments from authors with real or apparent conflicts of interest
- Comments that are rude, libelous, or inflammatory
- Comments that are anonymous or written under a pseudonym

We will publish your name with your response. You must provide an email address when a response is submitted, and this address will be made available to readers so they can contact you. Citations should be included only when essential and should be in the same format as used in *eNeuro*. Responses with more than a few citations will not be published.

All authors of responses are subject to the guidelines described in the [Responsible Conduct Regarding Scientific Communications](#). Responses must observe any licenses or copyrights on original material. Submitting authors are entirely responsible for the accuracy of the content of responses. However, we expect specific claims to be supported by references and opinion or speculation to be so specified in the response. Financial contributions to the work being reported should be clearly acknowledged, as should any potential conflict of interest. The proper form for citing journal responses is as follows:

- Smith, A.B., Title of response letter (electronic response to Jones, C.D., Title of original paper. *eNeuro* November/December 2014:1(1): e5813-14. DOI:10.1523/eNeuro e5813-12.2015).

## Media and Embargo Policies

The Society for Neuroscience (SfN) Media & Communications Department promotes research in its journals by providing embargoed early-release papers and recently published research to public information officers and reporters. Embargoes offer reporters time to prepare comprehensive, accurate stories before the research is officially released to the public. This lead time allows reporters to research, conduct interviews, and prepare their stories to coincide with publication of the study. This helps protect the public from inaccurate reporting of scientific information.

Authors may elect to have their papers delayed from publishing as an online early-release PDF for up to 19 days in order to participate in SfN press promotion. This election takes place at submission or if invited to submit a revision by selecting a check box to allow SfN's Media & Communications Department to consider the paper for highlighted promotion to science press. If selected, SfN will ensure that the drafted lay language headline and summary are approved by the corresponding author(s) prior to being released to the media. If an author agrees to the delay, but the paper is not selected to be promoted under the media embargo, the accepted paper will publish online in the normal early-release timeframe.

Only the *eNeuro* articles highlighted in the weekly media email sent on **Tuesdays** at 11 a.m. are embargoed for release to the public until 1 p.m. Eastern Time on the following Monday. This policy applies to members of the media, authors, public information officers, and anyone else with access to articles published in *eNeuro*. If a reporter contacts an author prior to publication, an author may share the manuscript and speak about it with the reporter as long as both parties agree not to release any information to the public until the embargo lifts.

Contact the SfN Media & Communications Department ([media@sfn.org](mailto:media@sfn.org)) for clarification on the official policies surrounding embargoes or for guidance on talking to reporters about your science.

## Media and Embargo Policies

The Society for Neuroscience (SfN) Media & Communications Department promotes research in its journals by providing embargoed early-release papers and recently published research to public information officers and reporters. Embargoes offer reporters time to prepare comprehensive, accurate stories before the research is officially released to the public. This lead time allows reporters to research, conduct interviews, and prepare their stories to coincide with publication of the study. This helps protect the public from inaccurate reporting of scientific information.

## Writing Tips

Below are tips on how to revise sentences. Both articles were published in SfN's Neuroscience Newsletter.

## Tips for Clear Writing

Overuse of the passive voice is a common problem in writing. Although passive voice has its place — for example, in the Methods section — in many instances it makes the manuscript dull by failing to identify the author's role in the research. Other weak writing practices are the overuse of prepositional phrases, the verb “to be,” nominalizations, and noun strings. Using too many prepositional phrases causes information overloads that can confuse readers. Overuse of the weak linking verb “to be” creates unnecessarily long and imprecise sentences. Sentences with many nominalizations (noun forms of verbs) result in texts that are difficult to understand. Energize your text by transforming the noun forms of verbs back into verbs and avoid noun strings (nouns modifying nouns), which result in too much compressed information that is confusing to readers. Consider, too, where to put new and important information. Generally, readers look for new information at the end of sentences, the end of paragraphs, and the end of abstracts. Help the reader locate your most important points by using these stress positions.

## Principles at Work

(See examples on [eNeuro](#))

- Use direct, active-voice sentences.
- Limit prepositional phrases.
- Limit use of the verb “to be.”
- Avoid noun forms of verbs (nominalizations).
- Limit noun strings (nouns modifying nouns).
- Put new and important information toward the end of sentences and paragraphs.

## Submitting a Manuscript

### Review Process



All manuscripts must be submitted to *eNeuro*'s web-based submission site. Please refer to requirements for submission before you begin. The author who completes the submission will be designated as the corresponding author and will be responsible for handling communications with *eNeuro*. Co-corresponding authors may be designated on the [proofs](#) for accepted articles. The submitting author has full authority to speak for all

other authors regarding withdrawal of a manuscript or correction or retraction of a published article.

At the time of submission, authors will be asked to direct their manuscript to one of *eNeuro*'s eight publishing topics and manuscript types. Authors will also be asked to choose one or two preferred reviewing editor(s) in order of preference. Editor assignments will be made based on the expertise of the editors, load, and scheduling. Accepted manuscripts will appear in the manuscript type and publishing topic selected by the authors.

Authors are requested to identify up to five reviewers who are well qualified to referee the work and would not have a conflict of interest. Authors may also exclude specific individuals from reviewing their manuscript. The reviewing editor will typically select two independent reviewers to evaluate each paper. Once a consensus is reached by the reviewers, authors will receive a fact-based synthesis of their reviewers' comments explaining why the work was accepted or rejected, which will be published alongside the article if accepted.

### **Reviewer Compliance with SfN Guidelines and Conflict of Interest Policy**

*eNeuro* seeks to avoid any real, potential and/or perceived conflicts of interest in the manuscript review process. To accomplish this, we ask reviewers to recognize potential competing interests that could lead them to be positively or negatively disposed towards an article and to recuse themselves if they feel that they are unable to offer an impartial review. Examples of conflicts of interest that would lead an invited reviewer and editors to exclude herself/himself include:

- Working at the same institution or organization as one or more of the authors, currently or recently (within the past 3 years);
- Having financial interests related to the manuscript;
- Presently collaborating, planning grant applications and/or manuscript preparation with one or more of the authors;
- Having served as an advisor or mentor to one or more of the authors during the past 10 years;
- Having been mentored, formally or informally, by one or more of the authors during the last 3 years;
- Having collaborated with or co-authored (one or more) publications with one or more of the authors during the past 3 years;
- Having held grants with one or more of the authors, during the past 3 years;
- Having a personal relationship with one or more of the authors that impacts the ability to evaluate the manuscript objectively.

Manuscripts will be returned without outside review if the reviewing editor deems that the paper is of insufficient general interest for the broad readership of *eNeuro*, or that the scientific quality is such that it is unlikely to receive favorable reviews. Editorial rejection allows authors to submit their papers elsewhere without further delay.

*eNeuro* is a member of the Neuroscience Peer Review Consortium, an alliance of neuroscience journals that have agreed to share manuscript reviews at the author's request. Its goals are to support efficient and thorough peer review of original research in neuroscience, to speed the publication of research reports, and to reduce the burden on peer reviewers. For information about the Consortium and instructions on how to forward reviews, please visit <http://nprc.incf.org/index.php/about/information-for-authors/>

## **Requirements for Submission**

### **Author Compliance with SfN Guidelines and Conflict of Interest Policy:**

<https://www.sfn.org/Membership/Professional-Conduct/Guidelines-for-Responsible-Conduct-Regarding-Scientific-Communication>

When submitting your manuscript at *eNeuro*'s electronic site, you will be asked to provide the following:

### **Manuscript Files**

- The manuscript should be organized as described in [Preparing Your Manuscript](#).
- Manuscripts must make no references to supplemental material.
- For invited revisions or resubmissions, you must submit the manuscript text in Word, WordPerfect, RTF, LaTeX, or Text format. Each figure must be uploaded as a separate file in TIFF or EPS format. Tables may be included either in the manuscript text file or as separate Word, WordPerfect, RTF, LaTeX, or Text files. PDF format is not accepted for the manuscript text, figures or tables.
- For new submissions, you may instead submit one PDF file that includes the manuscript text and all figures and tables. Pages must be numbered.

### **Title Page Information**

The title page of the manuscript should be completed using the available [template](#).

Please fill out the form completely and upload as a title page file.

Collect the following information to fill in the title page template:



- Title (50-word maximum)
- Abbreviated title (50-character maximum)
- Author names and affiliation, including postal codes
- Author contributions
  - Each author must be identified with at least one of the following: Designed research, performed research, contributed unpublished reagents/analytic tools, analyzed data, or wrote the paper. Note that writing the paper by itself is not an adequate basis for authorship.
- Corresponding author with complete address, including an email address and postal code
- Number of figures, tables, and multimedia (separately)
- Number of words for abstract, introduction, and discussion (separately)
- Acknowledgements
- Conflict of Interest
- Funding sources

**Title** (50 words maximum) **and Running Title** (50 characters maximum)

## Publishing Topic

- Authors must direct their manuscript to the appropriate publishing topic: development, neuronal excitability, sensory and motor systems, integrative systems, cognition and behavior, novel tools and methods, disorders of the nervous system, or history, teaching, and public awareness.

## Reviewers

- Authors are asked to identify reviewers who are well qualified to referee the work and who would not have a conflict of interest. Authors should provide the name, address, and email for each potential referee. Authors will also be asked to identify reviewers who should be excluded from refereeing. Do not include anyone with an intimate knowledge of your research.

## Editors

- Authors will be asked to choose [Reviewing Editor\(s\)](#) in order of preference.
- Assignments will be made based on expertise of the editors, load, and availability. Authors may exclude reviewing editors from handling their manuscripts.

## Cover Letter

- It is not necessary to include a cover letter, but you will be allowed to insert one on the submission form if you choose.

## No Submission Fee

## Checklist for Initial Submissions

For Registered Reports **Stage 1** checklist, [click here](#).

For Registered Reports **Stage 2** checklist, [click here](#).

- The submission may be either a single PDF file containing all text and figures (pages and figures must be numbered) or multiple files: a manuscript file in Word, WordPerfect, RTF, LaTeX, or Text format and each figure in a separate TIFF (300 dpi) or EPS file
- Source data files essential to the work are included.
- Individual files must always be used for multimedia (.MP4)
- The authors, title and abstract inserted on the submission form must match those in the separate title page and article file. The article file should not include a title page.
- Preferred reviewing editor(s) must be specified on the submission form. Excluded reviewing editors may also be included.
- Preferred and excluded reviewers may be specified on the submission form.
- Cover letter is optional.

### Text:

- No information that would identify any of the authors is present.
- Sections appear in the following order: Abstract, Significance Statement, Introduction, Materials and Methods, Results, Discussion, References, Figure/Table Legends, Figures, and Tables.
- All pages are double spaced and numbered.
- No broken URLs in text.
- No footnotes or appendices are present.
- No reference to supplemental material appears in the text, figures, or tables.

### Separate Title Page Includes:

- Title (50 words maximum)
- Abbreviated title (50 characters maximum)
- Names and affiliations of each author
- Author contributions
- Corresponding author's name and email address
- Number of figures, tables, and multimedia (separately)
- Number of words for Abstract, Introduction, and Discussion (separately, including any citations)
- Funding sources
- Conflicts of interest (if applicable)
- Acknowledgements

### Abstract:

- Word count is  $\leq 250$

- Species studied is identified in abstract (or title)
- No subheadings are present

**Significance Statement:**

- Word count is  $\leq 120$

**Introduction:**

- Word count is  $\leq 750$

**Materials and Methods:**

- Sex of subjects is stated (male, female, or of either sex).
- Companies or individuals (with full affiliations) from which unusual materials were obtained are provided.
- Statistical method used is stated (descriptive and/or experimental design (random or nonrandom)).
- Statistical table is included and listed in article text (i.e. Table XX.).
- To preserve the double-blind process, the following statement regarding animal use is used: "All animal procedures were performed in accordance with the [Author University] animal care committee's regulations."

**Results:**

- Detailed information on each analysis performed is included with specific *p* values.

**Discussion:**

- Word count is  $\leq 3,000$

**Citations:**

- Proper citation style for *eNeuro* is used.
- A reference is provided for each in-text citation, and *vice versa*.

**Figures and Multimedia:**

- Each illustration is numbered (separate numbering for figures and multimedia).
- Each illustration has a legend and is mentioned in the manuscript.
- All symbols are defined in the caption.

**Tables:**

- Each table is numbered and mentioned in the manuscript.
- Table contains no color or graphics.
- A legend and title are provided for each table.

author information, acknowledgements, conflict of interest, or funding sources.

- Individual table files are in Word format.
- Each table is in Text format and in black and white; no images or color allowed.

**Figures/Multimedia:**

- Each figure is in a separate TIFF (300 dpi) or EPS file.
- Each figure is in either RGB color mode or Grayscale format.
- A visually captivating image included to highlight the published article (landscape format,  $\geq 1,600$  pixels wide, EPS or TIFF).
- Individual files are provided for multimedia (.MP4).
- A preview image for each video (EPS or TIFF, 300 DPI) best capturing the main point.
- All illustrations are submitted at the size they should be published.
- Graphs and figures do not have gridlines or top/right borders.

**License to Publish Form**

- Sign the electronic [License to Publish form](#) once the revised manuscript is submitted. A link to the form will be available on the home page of [eNeuro.msubmit.net](http://eNeuro.msubmit.net) for each author, if the corresponding author does not sign for all authors.

---

## Revising/Finalizing a Manuscript

### Revisions

Detailed instructions for submitting a revised manuscript are included in the decision letter when a manuscript has been judged potentially acceptable for publication.

When submitting a revised manuscript you must:

- Submit revisions within three months of this the decision letter. If an extension is needed, contact the central journal office ([eNeuro@sfn.org](mailto:eNeuro@sfn.org)) before the deadline.
- Sign the electronic [License to Publish form](#) once the revised manuscript is submitted. A link to the form will be available on the home page of the manuscript submission page for each author, if the corresponding author does not sign for all authors.
- Submit a point-by-point reply to the reviews showing how reviewer concerns were addressed.
- Submit the manuscript text (including tables, if any) in Word, WordPerfect, RTF, LaTeX, or Text format. In addition to a clean copy of the manuscript, you must include a version with all

---

## Checklist for Submitting a Revised Manuscript

For Registered Reports **Revised Stage 2** checklist, [click here](#).

Requirements are the same as for initial submissions, with the following additions:

### Submission

**Text/Tables:**

- Manuscript file is in Word, WordPerfect, RTF, LaTeX, or Text format.
- Separate [Title Page](#) includes any changes on

insertions and deletions indicated, so that reviewers can easily see the changes you have made.

- If revisions require adding, deleting, or reordering of figures, tables, or equations, be sure that all in-text references to such items are renumbered as well.
- If the statement "All animal procedures were performed in accordance with the authors' university animal care committee's regulations" was used in the materials and methods section to preserve the double-blind process, please be sure to provide the full statement, including the name of the institution in the cover letter so it can be used if the article is accepted.
- Double-check that all in-text citations are in the reference list and that all references on the reference list have at least one corresponding in-text citation. Only published references should appear in the reference list at the end of the paper.
- In the case of 'in press' references (i.e., accepted for publication in a specific journal or book), the paper, which must be relevant for reviewers to see in order to make a well-informed evaluation, should be included as an [eNeuro.org](http://eNeuro.org) SfN Information for Authors separate document text file along with the submitted manuscript. In this case, the authors recognize the loss of anonymity. "Submitted" references should be cited only in text and in the following form: (unpublished observations). If the paper is accepted, the authors can then add their names, i.e., (A. B. Smith, C. D. Johnson, and E. Greene, unpublished observations). Submit publication quality digital figures, one per file (see [Multimedia, Figure and Table Guidelines](#)). Check all aspects of illustrations carefully to avoid alterations in the proofs (see also [Proofs](#)). All labels used in a figure should be explained in the legend. Double-check that all labels and symbols mentioned in the figure legend are on the final version of the figure. For questions regarding figure sizing and digital art preparation see [Figures](#).
- Scrutinize your paper at this time for any final corrections in style or substance. Changes at the proof stage are permitted only for corrections of factual errors, printer's errors, or quality of figure reproduction. Other changes may result in a fee.

## Proofs

Authors should be aware that *eNeuro* limits author alterations in proof. Only corrections of factual errors, copyediting errors, or in the quality of figure reproduction

are allowed. This step has been taken to reduce the time required to produce *eNeuro*. All [fees](#) must be paid before a manuscript will be published.

To speed publication of *eNeuro* authors are given 48 hours from receipt of proofs to make and return corrections. Authors should notify *eNeuro*'s central office, [eNeuro@sfn.org](mailto:eNeuro@sfn.org), if the proofs should be sent to an email address other than that of the corresponding author listed on the manuscript. To purchase reprints or to inquire about production charges or invoices, refer to the contact material included with the proofs.

Once a manuscript is accepted, authors' names can only be added, deleted, or altered with the approval of the editors. Requests for changes to the author list will delay publication of a manuscript.

## Correcting Errors in Published Articles

### Corrections

Authors who discover errors in articles they have published should have the corresponding author contact *eNeuro*'s central office ([eNeuro@sfn.org](mailto:eNeuro@sfn.org)) with a detailed description of the correction that is needed. Corrigenda (corrections of author's errors) and errata (corrections of publisher's errors) will be published at no charge to the authors. Requests for corrections that affect the interpretation or conclusions of a published article will be reviewed by the editors.

### Retractions

#### Author-Initiated Retractions

*eNeuro* will retract an article at the authors' request at any time unless it is under review for a possible violation of SfN's guidelines of [Responsible Conduct Regarding Scientific Communications](#). At the authors' option, the retraction notice may simply state that the article has been retracted at the authors' request. Alternatively, the authors may provide a brief explanation of the error(s) prompting the retraction. However, statements of retraction may not assign blame to specific authors or laboratories. To request a retraction, the corresponding author should contact the editor-in-chief ([eNeuroeditor@sfn.org](mailto:eNeuroeditor@sfn.org)).

In retraction statements, *eNeuro* clearly distinguishes between author-initiated retractions and those initiated by the editors because of violations of the Society for Neuroscience's guidelines.

#### Editorial Retractions

The editors reserve the right to retract an article at any time after publication without the consent of the authors if an investigation by an appropriate authority reveals a violation of the Society for Neuroscience Ethics Policy.